-
2
-
-
0036991860
-
Future directions in the treatment of pancreatic cancer
-
Haller DG: Future directions in the treatment of pancreatic cancer. Semin Oncol 29: 31-39, 2002.
-
(2002)
Semin Oncol
, vol.29
, pp. 31-39
-
-
Haller, D.G.1
-
3
-
-
0030964122
-
Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil
-
Burris H and Storniolo AM: Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 33: 18-22, 1997.
-
(1997)
Eur J Cancer
, vol.33
, pp. 18-22
-
-
Burris, H.1
Storniolo, A.M.2
-
4
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD. and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris III, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
Cripps, M.C.7
Portenoy, R.K.8
Storniolo, A.M.9
Tarassoff, P.10
Nelson, R.11
Dorr, F.A.12
Stephens, C.D.13
Von Hoff, D.D.14
-
5
-
-
0031824267
-
The role of gemcitabine in the treatment of other tumours
-
Carmichael J: The role of gemcitabine in the treatment of other tumours. Br J Cancer 78: 21-25, 1998.
-
(1998)
Br J Cancer
, vol.78
, pp. 21-25
-
-
Carmichael, J.1
-
6
-
-
0030722875
-
Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine
-
Carmichael J: Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine. Digestion 58: 503-507, 1997.
-
(1997)
Digestion
, vol.58
, pp. 503-507
-
-
Carmichael, J.1
-
7
-
-
0033647140
-
Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines
-
Pace E, Melis M, Siena L, Bucchieri F, Vignola AM, Profita M, Gjomarkaj M and Bonsignore G: Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines. Cancer Chemother Pharmacol 46: 467-476, 2000.
-
(2000)
Cancer Chemother Pharmacol
, vol.46
, pp. 467-476
-
-
Pace, E.1
Melis, M.2
Siena, L.3
Bucchieri, F.4
Vignola, A.M.5
Profita, M.6
Gjomarkaj, M.7
Bonsignore, G.8
-
8
-
-
0035007441
-
Gemcitabine in advanced bladder cancer
-
von der Maase H: Gemcitabine in advanced bladder cancer. Semin Oncol 28: 11-14, 2001.
-
(2001)
Semin Oncol
, vol.28
, pp. 11-14
-
-
Von Der Maase, H.1
-
9
-
-
0034886811
-
Gemcitabine in ovarian cancer
-
Orlando M and Mandachain M: Gemcitabine in ovarian cancer. Semin Oncol 28: 62-69, 2001.
-
(2001)
Semin Oncol
, vol.28
, pp. 62-69
-
-
Orlando, M.1
Mandachain, M.2
-
10
-
-
0033638288
-
The role of gemcitabine alone and in combination in the treatment of pancreatic cancer
-
Oettle H, Arnold D, Hempel C and Riess H: The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs 11: 771-786, 2000.
-
(2000)
Anticancer Drugs
, vol.11
, pp. 771-786
-
-
Oettle, H.1
Arnold, D.2
Hempel, C.3
Riess, H.4
-
11
-
-
0026640498
-
Activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units
-
Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, Grindey GB and Von Hoff DD: Activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anticancer Drugs 3: 143-146, 1992.
-
(1992)
Anticancer Drugs
, vol.3
, pp. 143-146
-
-
Hanauske, A.R.1
Degen, D.2
Marshall, M.H.3
Hilsenbeck, S.G.4
Grindey, G.B.5
Von Hoff, D.D.6
-
12
-
-
0028889426
-
Schedule-dependent antitumor effect of gemcitabine in in vivo model system
-
Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G and Peters GJ: Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 22: 42-46, 1995.
-
(1995)
Semin Oncol
, vol.22
, pp. 42-46
-
-
Braakhuis, B.J.1
Ruiz Van Haperen, V.W.2
Boven, E.3
Veerman, G.4
Peters, G.J.5
-
13
-
-
0029805907
-
Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine
-
San Antonio Drug Development Team
-
Von Hoff DD: Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team. Invest New Drugs 14: 265-270, 1996.
-
(1996)
Invest New Drugs
, vol.14
, pp. 265-270
-
-
Von Hoff, D.D.1
-
14
-
-
0031114142
-
Preclinical, pharmacologic, and phase I studies of gemcitabine
-
Storniolo AM, Allerheiligen SR and Pearce HL: Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 24: 72-77, 1997.
-
(1997)
Semin Oncol
, vol.24
, pp. 72-77
-
-
Storniolo, A.M.1
Allerheiligen, S.R.2
Pearce, H.L.3
-
15
-
-
0033198464
-
Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line
-
Goan YG, Zhou B, Hu E, Mi S and Yen Y: Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59: 4204-4207, 1999.
-
(1999)
Cancer Res
, vol.59
, pp. 4204-4207
-
-
Goan, Y.G.1
Zhou, B.2
Hu, E.3
Mi, S.4
Yen, Y.5
-
16
-
-
0033787983
-
Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer
-
Kornmann M, Butzer U, Blatter J, Beger HG and Link KH: Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. Eur J Surg Oncol 26: 583-587, 2000.
-
(2000)
Eur J Surg Oncol
, vol.26
, pp. 583-587
-
-
Kornmann, M.1
Butzer, U.2
Blatter, J.3
Beger, H.G.4
Link, K.H.5
-
17
-
-
0025297509
-
Polypetide core of a human pancreatic tumor mucin antigen
-
Lan MS, Hollingsworth MA and Metzgar RS: Polypetide core of a human pancreatic tumor mucin antigen. Cancer Res 50: 2997-3001, 1990.
-
(1990)
Cancer Res
, vol.50
, pp. 2997-3001
-
-
Lan, M.S.1
Hollingsworth, M.A.2
Metzgar, R.S.3
-
18
-
-
0029000780
-
Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium
-
Ho SB, Shekels LL, Toribara NW, Kim YS, Lyftogt C, Cherwitz DL and Niehans GA: Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res 55: 2681-90, 1995.
-
(1995)
Cancer Res
, vol.55
, pp. 2681-2690
-
-
Ho, S.B.1
Shekels, L.L.2
Toribara, N.W.3
Kim, Y.S.4
Lyftogt, C.5
Cherwitz, D.L.6
Niehans, G.A.7
-
19
-
-
0031106545
-
Biology, biochemistry and immunology of carcinoma-associated mucins
-
Taylor-Papadimitriou J and Finn OJ: Biology, biochemistry and immunology of carcinoma-associated mucins. Immunol Today 18: 105-107, 1997.
-
(1997)
Immunol Today
, vol.18
, pp. 105-107
-
-
Taylor-Papadimitriou, J.1
Finn, O.J.2
-
20
-
-
0026474723
-
Mucin gene expression in colonic tissues and cell lines
-
Ogata S, Uehara H, Chen A and Itzkowitz SH: Mucin gene expression in colonic tissues and cell lines. Cancer Res 52: 5971-5978, 1992.
-
(1992)
Cancer Res
, vol.52
, pp. 5971-5978
-
-
Ogata, S.1
Uehara, H.2
Chen, A.3
Itzkowitz, S.H.4
-
21
-
-
0025774355
-
Differential mucin gene expression in human pancreatic and colon cancer cells
-
Yonezawa S, Byrd JC, Dahiya R, Ho JJ, Gum JR, Griffiths B, Swallow DM and Kim YS: Differential mucin gene expression in human pancreatic and colon cancer cells. Biochem J 276: 599-605, 1991.
-
(1991)
Biochem J
, vol.276
, pp. 599-605
-
-
Yonezawa, S.1
Byrd, J.C.2
Dahiya, R.3
Ho, J.J.4
Gum, J.R.5
Griffiths, B.6
Swallow, D.M.7
Kim, Y.S.8
-
22
-
-
0024454148
-
Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells
-
Barnd DL, Lan MS, Metzgar RS and Finn OJ: Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86: 7159-7163, 1989.
-
(1989)
Proc Natl Acad Sci USA
, vol.86
, pp. 7159-7163
-
-
Barnd, D.L.1
Lan, M.S.2
Metzgar, R.S.3
Finn, O.J.4
-
23
-
-
0027234878
-
Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides
-
Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT and Finn OJ: Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151: 3693-3703, 1993.
-
(1993)
J Immunol
, vol.151
, pp. 3693-3703
-
-
Ioannides, C.G.1
Fisk, B.2
Jerome, K.R.3
Irimura, T.4
Wharton, J.T.5
Finn, O.J.6
-
24
-
-
0028989973
-
MUC-1 epithelial tumor mucin-based immunity and cancer vaccines
-
Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J and Barratt-Boyes SM: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145: 61-89, 1995.
-
(1995)
Immunol Rev
, vol.145
, pp. 61-89
-
-
Finn, O.J.1
Jerome, K.R.2
Henderson, R.A.3
Pecher, G.4
Domenech, N.5
Magarian-Blander, J.6
Barratt-Boyes, S.M.7
-
25
-
-
0031297362
-
Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen
-
Apostolopoulos V, Karanikas V, Haurum JS and McKenzie IF: Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159: 5211-5218, 1997.
-
(1997)
J Immunol
, vol.159
, pp. 5211-5218
-
-
Apostolopoulos, V.1
Karanikas, V.2
Haurum, J.S.3
McKenzie, I.F.4
-
26
-
-
0033564363
-
Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
-
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L and Brugger W: Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93: 4309-4317, 1999.
-
(1999)
Blood
, vol.93
, pp. 4309-4317
-
-
Brossart, P.1
Heinrich, K.S.2
Stuhler, G.3
Behnke, L.4
Reichardt, V.L.5
Stevanovic, S.6
Muhm, A.7
Rammensee, H.G.8
Kanz, L.9
Brugger, W.10
-
27
-
-
17844402226
-
Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes
-
Kontani K, Taguchi O, Narita T, Izawa M, Hiraiwa N, Zenita K, Takeuchi T, Murai H, Miura S and Kannagi R: Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer 84: 1258-1264, 2001.
-
(2001)
Br J Cancer
, vol.84
, pp. 1258-1264
-
-
Kontani, K.1
Taguchi, O.2
Narita, T.3
Izawa, M.4
Hiraiwa, N.5
Zenita, K.6
Takeuchi, T.7
Murai, H.8
Miura, S.9
Kannagi, R.10
-
28
-
-
0036453668
-
Mucin gene (MUC1) transfected dendritic cells as vaccine: Results of a phase I/II clinical trial
-
Pecher G, Haring A, Kaiser L and Thiel E: Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51: 669-673, 2002.
-
(2002)
Cancer Immunol Immunother
, vol.51
, pp. 669-673
-
-
Pecher, G.1
Haring, A.2
Kaiser, L.3
Thiel, E.4
-
29
-
-
0034331218
-
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
-
Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L and Brugger W: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108, 2000.
-
(2000)
Blood
, vol.96
, pp. 3102-3108
-
-
Brossart, P.1
Wirths, S.2
Stuhler, G.3
Reichardt, V.L.4
Kanz, L.5
Brugger, W.6
-
30
-
-
0033472707
-
Adriamycin activates E-cadherin-mediated cell-cell adhesion in human breast cancer cells
-
Yang SZ, Kohno N, Kondo K, Yokoyama A, Hamada H, Hiwada K and Miyake M: Adriamycin activates E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Int J Oncol 15: 1109-1115, 1999.
-
(1999)
Int J Oncol
, vol.15
, pp. 1109-1115
-
-
Yang, S.Z.1
Kohno, N.2
Kondo, K.3
Yokoyama, A.4
Hamada, H.5
Hiwada, K.6
Miyake, M.7
-
31
-
-
0021061819
-
Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
-
Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
-
(1983)
J Immunol Methods
, vol.65
, pp. 55-63
-
-
Mosmann, T.1
-
32
-
-
0025101209
-
Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies
-
Xing PX, Reynolds K, Tjandra JJ, Tang XL and McKenzie IF: Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies. Cancer Res 50: 89-96, 1990.
-
(1990)
Cancer Res
, vol.50
, pp. 89-96
-
-
Xing, P.X.1
Reynolds, K.2
Tjandra, J.J.3
Tang, X.L.4
McKenzie, I.F.5
-
33
-
-
0024374660
-
Reactivity of anti-human milk fat globule antibodies with synthetic peptides
-
Xing PX, Tjandra JJ, Reynolds K, McLaughlin PJ, Purcell DF and McKenzie IF: Reactivity of anti-human milk fat globule antibodies with synthetic peptides. J Immunol 142: 3503-3509, 1989.
-
(1989)
J Immunol
, vol.142
, pp. 3503-3509
-
-
Xing, P.X.1
Tjandra, J.J.2
Reynolds, K.3
McLaughlin, P.J.4
Purcell, D.F.5
McKenzie, I.F.6
-
34
-
-
0037089545
-
Gemcitabine exerts a selective effect on the humoral immune response: Implications for combination chemo-immunotherapy
-
Nowak AK, Robinson BW and Lake RA: Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62: 2353-2358, 2002.
-
(2002)
Cancer Res
, vol.62
, pp. 2353-2358
-
-
Nowak, A.K.1
Robinson, B.W.2
Lake, R.A.3
-
35
-
-
0031760361
-
2′-2′-d/fluorodeoxycytidine: In vitro effects on cell-mediated immune response
-
Alvino E, Fuggetta MP, Tricarico M and Bonmassar E: 2′-2′ -d/fluorodeoxycytidine: in vitro effects on cell-mediated immune response. Anticancer Res 18: 3597-3602, 1998.
-
(1998)
Anticancer Res
, vol.18
, pp. 3597-3602
-
-
Alvino, E.1
Fuggetta, M.P.2
Tricarico, M.3
Bonmassar, E.4
-
36
-
-
0036462584
-
Determinants of resistance to 2′,2′-d/fluorodeoxycytidine (gemcitabine)
-
Bergman AM, Pinedo HM and Peters GJ: Determinants of resistance to 2′,2′-d/fluorodeoxycytidine (gemcitabine). Drug Resist Update 5: 19-33, 2002.
-
(2002)
Drug Resist Update
, vol.5
, pp. 19-33
-
-
Bergman, A.M.1
Pinedo, H.M.2
Peters, G.J.3
-
37
-
-
0037137849
-
Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
-
Cardillo TM, Blumenthal R, Ying Z and Gold DV: Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer 97: 386-92, 2002.
-
(2002)
Int J Cancer
, vol.97
, pp. 386-392
-
-
Cardillo, T.M.1
Blumenthal, R.2
Ying, Z.3
Gold, D.V.4
-
38
-
-
0035892304
-
Overexpression of MUC1 reconfigures the binding properties of tumor cells
-
McDermott KM, Crocker PR, Harris A, Burdick MD, Hinoda Y, Hayashi T, Imai K and Hollingsworth MA: Overexpression of MUC1 reconfigures the binding properties of tumor cells. Int J Cancer 94: 783-791, 2001.
-
(2001)
Int J Cancer
, vol.94
, pp. 783-791
-
-
McDermott, K.M.1
Crocker, P.R.2
Harris, A.3
Burdick, M.D.4
Hinoda, Y.5
Hayashi, T.6
Imai, K.7
Hollingsworth, M.A.8
-
39
-
-
0033761311
-
Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule
-
Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K and Hollingsworth MA: Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int J Cancer 88: 507-518, 2000.
-
(2000)
Int J Cancer
, vol.88
, pp. 507-518
-
-
Satoh, S.1
Hinoda, Y.2
Hayashi, T.3
Burdick, M.D.4
Imai, K.5
Hollingsworth, M.A.6
|